Which Medical Conditions Qualify for Cannabis in the UK?
Medical Conditions Qualifying for Cannabis Prescription in the UK
Medical cannabis has been legal in the UK since November 2018, though access remains limited and strictly regulated. The following conditions represent those where cannabis-based medicinal products (CBMPs) may be prescribed by specialist doctors. Patients must have exhausted conventional treatment options before consideration for cannabis therapy.
Chronic Pain
Chronic pain is one of the most common conditions for which medical cannabis is prescribed in the UK. This includes various pain conditions lasting longer than 12 weeks, such as neuropathic pain, cancer-related pain, and musculoskeletal pain that has not responded adequately to conventional medications.
Cannabis-based products may help manage chronic pain through interaction with the endocannabinoid system, which plays a role in pain perception and modulation. Patients often report improved pain control and enhanced quality of life when conventional analgesics have failed or produced unacceptable side effects.
Post-Traumatic Stress Disorder (PTSD)
Post-traumatic stress disorder, a severe anxiety disorder following traumatic experiences, is increasingly recognised as a potential indication for medical cannabis. Eligible patients typically have failed to respond to conventional psychological therapies and medications such as SSRIs.
Evidence suggests that cannabinoids may help reduce hyperarousal, intrusive thoughts, and nightmares associated with PTSD. However, specialist assessment is essential to determine suitability, as cannabis can worsen anxiety in some individuals.
Anxiety Disorders
Certain anxiety disorders that have not responded to standard treatments including cognitive behavioural therapy and antidepressants may be considered for medical cannabis prescription. This includes generalised anxiety disorder, social anxiety, and treatment-resistant anxiety conditions.
CBD (cannabidiol), in particular, has shown anxiolytic properties in research settings. However, THC (tetrahydrocannabinol) can paradoxically increase anxiety in some patients, making careful formulation and dosing critical for this indication.
Epilepsy
Epilepsy, particularly drug-resistant epilepsy, represents one of the strongest indications for medical cannabis in the UK. This applies specifically to severe forms such as Dravet syndrome and Lennox-Gastaut syndrome that have not responded adequately to multiple anti-epileptic medications.
CBD has demonstrated significant anticonvulsant properties in clinical trials, with the licensed medicine Epidyolex approved for specific rare epilepsy types. Many patients with refractory epilepsy have experienced substantial reductions in seizure frequency when treated with cannabis-based products.
Multiple Sclerosis (MS)
Multiple sclerosis patients experiencing spasticity, pain, and other MS-related symptoms that have not adequately responded to conventional treatments may be eligible for medical cannabis prescriptions. MS-related spasticity represents a particularly recognised indication.
Cannabis-based products have demonstrated efficacy in reducing muscle spasticity and associated pain in MS. The Sativex nasal spray, a cannabis-derived medicine, has long been used in the UK for MS-related spasticity management.
Fibromyalgia
Fibromyalgia, a chronic condition characterised by widespread musculoskeletal pain, fatigue, and sleep disturbances, may qualify for medical cannabis consideration when conventional pain management and psychological therapies have proven insufficient.
Patients with fibromyalgia often present with multiple symptoms including pain, sleep dysfunction, and mood disturbances. Cannabis may address several of these symptoms simultaneously, potentially improving overall wellbeing and functional capacity.
Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome, particularly severe cases with treatment-resistant symptoms, represents a potential indication for medical cannabis. This applies especially to IBS characterised by significant abdominal pain and cramping unresponsive to standard medications.
The endocannabinoid system plays a role in gastrointestinal motility and pain sensation. Medical cannabis may help reduce visceral pain and improve bowel function in some IBS patients, though more research is needed.
ADHD (Attention Deficit Hyperactivity Disorder)
ADHD represents an emerging and more controversial indication for medical cannabis in the UK. It may only be considered in adult patients who have not adequately responded to licensed ADHD medications or who cannot tolerate conventional treatments due to side effects.
Evidence for cannabis treatment in ADHD remains limited and mixed. Specialist psychiatric assessment is essential before any consideration, as stimulant medications remain first-line treatment and cannabis may worsen symptoms in some individuals.
Evidence Levels and Clinical Assessment
| Condition | Evidence Level | Prescription Likelihood |
|---|---|---|
| Epilepsy (drug-resistant) | Strong | High |
| MS-related spasticity | Strong | High |
| Chronic pain | Moderate | Moderate-High |
| PTSD | Emerging | Moderate |
| Anxiety | Emerging | Moderate |
| Fibromyalgia | Limited | Low-Moderate |
| IBS | Limited | Low |
